

Christopher J Cheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11645797/publications.pdf>

Version: 2024-02-01

24
papers

3,005
citations

361413

20
h-index

610901

24
g-index

25
all docs

25
docs citations

25
times ranked

5801
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved CRISPR genome editing using small highly active and specific engineered RNA-guided nucleases. <i>Nature Communications</i> , 2021, 12, 4219.	12.8	29
2	miR-155 drives oncogenesis by promoting and cooperating with mutations in the c-Kit oncogene. <i>Oncogene</i> , 2019, 38, 2151-2161.	5.9	21
3	Exercise and weight loss interventions and miRNA expression in women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 55-67.	2.5	25
4	Leveraging Rational Protein Engineering to Improve mRNA Therapeutics. <i>Nucleic Acid Therapeutics</i> , 2018, 28, 74-85.	3.6	8
5	A "top-down" approach to actuate poly(amine-co-ester) terpolymers for potent and safe mRNA delivery. <i>Biomaterials</i> , 2018, 176, 122-130.	11.4	49
6	In vivo correction of anaemia in β^2 -thalassemic mice by β^3 PNA-mediated gene editing with nanoparticle delivery. <i>Nature Communications</i> , 2016, 7, 13304.	12.8	143
7	miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2016, 76, 927-939.	0.9	128
8	A holistic approach to targeting disease with polymeric nanoparticles. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 239-247.	46.4	373
9	miR-155 Is Essential for Inflammation-Induced Hippocampal Neurogenic Dysfunction. <i>Journal of Neuroscience</i> , 2015, 35, 9764-9781.	3.6	83
10	Systemic delivery of blood-brain barrier-targeted polymeric nanoparticles enhances delivery to brain tissue. <i>Journal of Drug Targeting</i> , 2015, 23, 736-749.	4.4	73
11	Enhancing potency of siRNA targeting fusion genes by optimization outside of target sequence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E6597-605.	7.1	11
12	MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. <i>Nature</i> , 2015, 518, 107-110.	27.8	709
13	Sustained delivery of proangiogenic microRNA-132 by nanoparticle transfection improves endothelial cell transplantation. <i>FASEB Journal</i> , 2014, 28, 908-922.	0.5	72
14	Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3062-71.	7.1	31
15	Regeneration of mammalian cochlear and vestibular hair cells through Hes1/Hes5 modulation with siRNA. <i>Hearing Research</i> , 2013, 304, 91-110.	2.0	34
16	Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013, 9, 1124-1134.	3.3	51
17	Canonical and Non-Canonical Barriers Facing AntimiR Cancer Therapeutics. <i>Current Medicinal Chemistry</i> , 2013, 20, 3582-3593.	2.4	48
18	A novel polymer-coated nanoparticle (NP) for urothelium penetration and drug delivery.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15543-e15543.	1.6	0

#	ARTICLE	IF	CITATIONS
19	The Duality of OncomiR Addiction in the Maintenance and Treatment of Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 232-237.	2.0	48
20	Surface modified poly(β amino ester)-containing nanoparticles for plasmid DNA delivery. <i>Journal of Controlled Release</i> , 2012, 164, 41-48.	9.9	75
21	Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery. <i>Nature Materials</i> , 2012, 11, 82-90.	27.5	360
22	Polymer Nanoparticle-Mediated Delivery of MicroRNA Inhibition and Alternative Splicing. <i>Molecular Pharmaceutics</i> , 2012, 9, 1481-1488.	4.6	84
23	Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E1695-704.	7.1	439
24	Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. <i>Biomaterials</i> , 2011, 32, 6194-6203.	11.4	106